Single Ascending Dose Study of PRX003 in Healthy Subjects

Summary

This single ascending dose study is to determine safety, tolerability, pharmacokinetics and immunogenicity of PRX003 in approximately 40 healthy subjects.

Timeline

Start

2015-05

Primary completion

2016-02

Completion

2016-02

Outcome

Met primary endpoint

release “All doses of PRX003 found to be safe and well tolerated, meeting the primary objective of the Phase 1 single ascending dose study in healthy volunteers” prothena.com ↗

Drugs

Indications